Vulnerabilities to Health Disparities and Statin Use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study

Abstract

BackgroundStatins may be underutilized in certain vulnerable populations, but the effect of cumulative vulnerabilities within 1 individual is not well described. We sought to determine the likelihood of receiving statins with an increasing number of vulnerabilities in an individual, after controlling for factors known to influence health services utilization.Methods and ResultsWe identified 18 216 participants from the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study who had a statin indication or who were taking statins, as verified by pill bottle review. Statin use was assessed with respect to 5 major vulnerability domains alone and in combination: older age, black race, female sex, high area‐level poverty, and lack of health insurance. The study included 5286 white men, 4180 black men, 2791 white women, and 4194 black women; 5.6% of the sample had no vulnerabilities, 20.6% had 1 vulnerability, 29.2% had 2 vulnerabilities, 27.3% had 3 vulnerabilities, and 17.3% had 4 or 5 vulnerabilities. All race–sex groups were less likely than white men to use statins; prevalence of use was 0.80 in black women with reference to white men (P<0.0001). In both unadjusted and adjusted models, as the number of vulnerabilities increased, statin use steadily decreased. After adjusting for factors that influence health services utilization, compared with those without any vulnerabilities, statin use prevalence was 0.91, 0.83, 0.74 and 0.68 (P<0.0001) in those with 1, 2, 3, and 4 or 5 vulnerabilities, respectively.ConclusionsParticipants with more simultaneously occurring vulnerabilities experienced the greatest disparities in statin use. Black women and those without health insurance were at particularly high risk of underutilization.

Pentagalloyl Glucose and Its Functional Role in Vascular Health: Biomechanics and Drug-Delivery Characteristics

“…166 With this observation, statins (hydroxymethylglutaryl-coenzyme A reductase inhibitors) and other lipid lowering drugs have been widely used for clinical studies, which have reported a decrease in AAA expansion rates. 57,81,145 Yet, the effect of statins has been ambivalent for most AAA cases, 48,82,149 and there is an undetermined possibility of cancer development 179 and adverse musculoskeletal and connective tissue disorders with statin use. 58 Doxycycline is one of the most studied drugs in AAA preclinical models 52 with the potential to inhibit MMP-2 and −9 174 and decrease AAA growth.…”

“…(c) Thirugnanasambandam et al . 149 utilized a similar rat calcium chloride model and utilized PGG to suppress aneurysm growth. As shown, PGG treatment was also able to suppress MMP influx to the aorta, which led to a reduction of inflammation.…”

Secondary prevention among uninsured stroke patients: A free clinic study

“…female sex and black race, or uninsured and black race) predicted an even lower rate of statin use compared to groups. 10 These socioeconomic barriers preclude appropriate secondary medical management for stroke in this population.…”

Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials

“…5 Differences in genetic traits, poor glycemic control, a high incidence of obesity, and the presence of insulin resistance contribute to this increased risk, which may be linked to racial disparities in health care. 14 Lower rates of statin use by AA/B vs W patients have been demonstrated in primary care populations, 15,16 reaffirming the disparities in the treatment of CVD, which is the first and second leading cause of death in AA/B and H/L patients, respectively. 17 In a retrospective study that used the 2015 Patient and Provider Assessment of Lipid Management registry data, AA/B patients were less likely than W to be treated with a statin (70.6% vs 74.8%, respectively; P 5 .02).…”